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Aortic stenosisSymptomatic severe aortic stenosis (AS) has a serious impact on
the quality of life in elderly patients and open-heart surgery has
been the only option as radical solution. However, elderly patients
have latent multiple organ dysfunctions, and postoperative
morbidity and mortality increase progressively with increasing
age. Transcatheter aortic valve replacement (TAVR), also called
transcatheter aortic valve implantation (TAVI), has emerged as an
alternative treatment for such patients who are at high risk for
open-heart surgery. This minimally invasive surgical procedure
wedges a replacement valve into the aortic valve’s place using
catheters. Watanabe et al. [1] reported that the outcome after TAVR
was acceptable and safe in Japanese elderly patients. TAVR is
associated with a signiﬁcantly higher incidence of vascular
complications, permanent pacemaker requirement, and moderate
or severe aortic regurgitation, whereas patients who undergo
surgical aortic valve replacement (SAVR) are more likely to
experience major bleeding [2]. Incidentally, valve leaﬂets are
mounted directly on the thin stents of prosthesis in TAVR [3], and
prosthesis–patient mismatch is theoretically improbable unless
the expansion is insufﬁcient. TAVR is now approved in over
60 countries across the world and has been performed in more than
70,000 patients. However, there are several points that concern us.
First, the most important concern is about the body size of
Japanese elderly patients as the authors highlighted in this paper
[1]. The average height of Japanese with an age of more than
80 years is 159.8 cm in males and 145.3 cm in females. The average
weight is 58.7 kg and 47.3 kg, respectively [4]. The sizes of aorta and
sinus of Valsalva are in relation to the body size. These are
associated with the selection of an approach site and the rupture of
aortic root when expanding a prosthetic valve. On the other hand,
the presence of signiﬁcant postprocedural paravalvular regurgita-
tion is an independent risk factor for mortality [5]. In other words,
minimizing paravalvular regurgitation is critical, whereas excessive
oversizing can lead to annular rupture. Thus, predicting the proper
size of ballooning before the procedure is crucial for the success ofDOI of original article: http://dx.doi.org/10.1016/j.jjcc.2014.05.001
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annular sizing is established with multidetector computed
tomography (CT) [6,7]. Aortic annular evaluation using CT is now
gold standard and the routine application is likely to reduce
complications. In addition, the information of calciﬁcation at the
aortic annulus, aortic valve leaﬂet, and sinotubular junction is also
useful for the assessment of the risk of annular rupture, coronary
occlusion, and aortic injury. If the position of ostium of coronary
arteries is low, especially in a case of small size of Valsalva sinus,
there is a risk of coronary occlusion by the thickened aortic valve
leaﬂet. Today’s success of TAVR would be not achievable without
the understanding of the risk factors. In Japanese elderly, we need
to consider these factors in more detail on the basis of ﬁndings on
CT imaging before the procedure.
The second concern is about correct positioning and deploy-
ment of the prosthetic valve. Malpositioning of the valve can occur,
when it is deployed too high or too low in relation to the aortic
annulus [8]. Then, that may be associated with adverse outcomes,
such as paravalvular regurgitation, coronary occlusion, left bundle
branch block, mitral insufﬁciency, and aortic injury. If the valve is
malpositioned too high, it can embolize into the aorta or the valve
may migrate into the left ventricle when the valve is malpositioned
too low. In the elderly, especially those with hypertension,
subaortic septal bulge due to sigmoid septum is sometimes
observed despite not being hypertrophic cardiomyopathy. This
may also cause malpositioning of the prosthesis because the
system can slip during balloon inﬂation. Accordingly, at the time of
deployment, stepwise, not rapid, balloon inﬂation is now
recommended, because the correction of deployment position is
possible.
Third, only balloon-expandable Edwards SAPIEN XT valve
(Edwards Life Sciences, Irvine, CA, USA) is currently commercially
available in Japan, but self-expandable Medtronic CoreValve
device (Medtronic, St. Paul, MN, USA), which has received CE
Mark approval in Europe is not yet. Each of these prostheses has its
merits and demerits [9]. The Edwards SAPIEN XT may be implanted
using a transfemoral or transapical approach, while the Medtronic
CoreValve system can be delivered through a femoral, subclavian,
or direct aortic approach. In patients with small femoral arteries or
arteriosclerosis obliterans, we are forced to select transapical
approach at the moment. However, when pulling out the sheath,
stopping of bleeding may be easier in direct aortic approach than in
transapical approach because the heart is beating but the aorta is
not. It is wished that the alternatives soon become available. reserved.
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1 year than SAVR in high-risk subjects [10]. TAVR is now
generally accepted for treatment of high-risk or inoperable
patients, but the valve durability of prosthesis is still unknown. It
is also unclear how we deﬁne debility or frailty in candidates.
Although there are concerns in TAVR, while inheriting the
forerunners’ experience, by the technical improvement in the
procedure as well as the careful patient selection, safe and
effective TAVR is promising in Japan.
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